All In Biotech

Drug Trial Radar · NCT02614794

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

Last checked: Nov 20, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 612 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

612

Actual

Start

Jan 28, 2016

Primary completion

Sep 4, 2019

Study completion Aug 11, 2022

Sponsor

Lead sponsor
Seagen Inc.Pfizer (PFE)
Sponsor type
Industry
First posted
Nov 25, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to see if tucatinib works better than placebo to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. All patients in the study will get capecitabine and trastuzumab, two drugs that are often used to treat this cancer. There are two parts to this study. The first part of the study is already complete. Patients were randomly assigned to get either tucatinib or placebo (a pill with no medicine). Since this part was "blinded," neither patients nor their doctors knew whether a patient got tucatinib or placebo. The second part of the study is called the Unblinded Phase. In this part of the study, participants and their doctors know which drugs are being given. Participants who used to get or are currently getting placebo may be able to start taking tucatinib instead. Each treatment cycle lasts 21 days. Patients will swallow tucatinib pills two times every day. They will swallow capecitabine pills two times a day during the first two weeks of each cycle. Patients will get trastuzumab injections from the study site staff on the first day of every cycle.

Conditions

  • HER2 Positive Breast Cancer

Interventions

  • tucatinibDrug

    300 mg orally twice daily

  • capecitabineDrug

    1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle

  • trastuzumabDrug

    8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.

  • placeboDrug

    Oral dose twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR)Time frame: 34.6 months

Locations

176 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of South Alabama - Mitchell Cancer Institute

    Mobile, Alabama

  • Cancer Treatment Centers of America - Phoenix

    Goodyear, Arizona

  • Arizona Oncology Associates, PC - HAL

    Phoenix, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • TRIO - Central Regulatory Office

    Los Angeles, California

  • UCLA Medical Center / David Geffen School of Medicine

    Los Angeles, California

  • Torrance Memorial Physician Network - TRIO

    Redondo Beach, California

  • University of California at San Francisco

    San Francisco, California

  • Kaiser Permanente San Marcos Medical Offices

    San Marcos, California

  • Central Coast Medical Oncology Corporation TRIO

    Santa Maria, California

  • Kaiser Permanente Medical Center Northern California

    Vallejo, California

  • University of Colorado Hospital / University of Colorado

    Aurora, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Lombardi Cancer Center / Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Florida Cancer Specialists - South Region

    Fort Myers, Florida

  • Memorial Regional Hospital TRIO

    Hollywood, Florida

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • Mount Sinai Medical Center / Florida

    Miami Beach, Florida

  • Orlando Health, Inc. TRIO

    Orlando, Florida

  • Florida Cancer Specialists - North Region

    St. Petersburg, Florida

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Florida Cancer Specialists - East West Palm Beach, FL (SCRI)

    West Palm Beach, Florida

  • Winship Cancer Institute / Emory University School of Medicine

    Atlanta, Georgia

  • Northside Hospital

    Atlanta, Georgia

  • Augusta University

    Augusta, Georgia

  • Cancer Treatment Centers of America

    Newnan, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Illinois Cancer Specialists / Advocate Lutheran General Hospital

    Niles, Illinois

  • Carle Cancer Center

    Urbana, Illinois

  • University of Kansas Cancer Center

    Westwood, Kansas

  • University of Maryland

    Baltimore, Maryland

  • Maryland Oncology Hematology, P.A.

    Rockville, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • William Beaumont Hospital

    Royal Oak, Michigan

  • Virginia Piper Cancer Institute

    Minneapolis, Minnesota

  • Saint Luke's Cancer Institute LLC

    Kansas City, Missouri

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.